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ccurrence of heavy-chain antibodies in camelids
Antibodies throughout mammalian species are com-
ed of two identical H-chains and two identical L-chains
. 1A). The IgG antibodies from species of camelidae (i.e.
elus dromedarius, Camelus bactrianus, Lama glama, Lama
noco, Lama alpaca and Lama vicugna) form a surprising
exception to this paradigm as their serum contains also a
considerable fraction of heavy-chain antibodies (HCAbs),
that lack the L-chain (Hamers-Casterman et al., 1993). The
H-chain within the HCAbs is composed of three instead of
four globular domains (Fig. 1A). The two constant domains
are highly homologous to the Fc domains (CH2–CH3) of
classical antibodies (Nguyen et al., 1999; Woolven et al.,
1999). The domain corresponding to the CH1 domain of
classical antibodies ismissing inHCAbs. Hence, the antigen-
binding fragment of a classical antibody, the Fab, is reduced
to a single variable domain in the HCAb (Fig. 1A). This
variable domain referred to as VHH is adapted to become
functional in antigen binding in absence of a variable light
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It is well established that all camelids have unique antibodies circulating in their blood.
Unlike antibodies from other species, these special antibodies are devoid of light chains and
are composedof aheavy-chainhomodimer. These so-calledheavy-chain antibodies (HCAbs)
are expressed after a V–D–J rearrangement and require dedicated constant g-genes. An
immune response is raised in these so-called heavy-chain antibodies following classical
immunization protocols. These HCAbs are easily purified from serum, and the antigen-
binding fragment interacts with parts of the target that are less antigenic to conventional
antibodies. Since the antigen-binding site of the dromedaryHCAb is comprised in one single
domain, referred to as variable domain of heavy chain of HCAb (VHH) or nanobody (Nb), we
designed a strategy to clone theNb repertoire of an immunized dromedary and to select the
Nbs with specificity for our target antigens. The monoclonal Nbs are well produced in
bacteria, are very stable andhighly soluble, and bind their cognate antigenwith high affinity
and specificity. We have successfully developed recombinant Nbs for research purposes,
as probe in biosensors, to diagnose infections, and to treat diseases like cancer or
trypanosomosis.
 2008 Elsevier B.V. All rights reserved.
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1997; Harmsen et al., 2001; Maass et al., 2007). It has been
repeatedly demonstrated that the VHH, cloned and
expressed in bacteria, is a strictly monomeric, single-
domain antigen-binding entity (Muyldermans and Lauwer-
eys, 1999). The publicity around nanotechnology and the
prolate shape (i.e. shaped like a rugby ball) in the nm range
(diameter of 2.5 nm and height of 4 nm) of the VHH
stimulated Ablynx – the company focusing on therapeutic
applications of camelid antibodies – to rename VHH’s as
nanobodies (Nbs).
The organization is remarkably similar between the
variable domain of the H-chain of a classical antibody and
that of an HCAb, the VH and VHH, respectively. Never-
theless the VH and VHH contain minor, but important
differences that explain the antigen-binding capacity of
the VHH’s in a single-domain format (Conrath et al., 2003).
Both domains are composed of four conserved sequence
stretches, the framework regions, surrounding three
hypervariable regions, the complementarity determining
regions (CDR) (Fig. 1B). The VH and VHH domains adopt an
Ig fold of two b-sheets, one of four strands and one of five
strands (Muyldermans et al., 2001; Padlan, 1994). Within
this fold, the three hypervariable regions, clustering at one
end of the domain, are located in loops that connect the b-
strands where they participate in antigen recognition. The
alignment of the VH and VHH amino acid sequences
immediately reveals that the first and third hypervariable
regions of the VHH are more extended than those of VH’s,
and in dromedary but not in llama, the CDR1 and CDR3
often contain a Cys (Conrath et al., 2003). From crystal
structures of VHH we know that these Cys form a disulfide
bond that possibly assists in shaping the loop structure (De
Genst et al., 2006b; Muyldermans et al., 2001). Another
striking distinction between VH and VHH occurs in the
framework-2 region. This region is normally highly
conserved in VH domains and populated by hydrophobic
amino acids that serve as an anchoring place for the VL
domain. In contrast the corresponding region in a VHH
contains more hydrophilic amino acids (Fig. 1B), which
explains the absence of VL association and the soluble
behavior of VHH as a single-domain entity (Nguyen et al.,
2001).
The paratope of a classical antibody is expected to be
much larger than that of a VHH due to the presence of the
three CDR’s in the VL domain. However, it has been
proposed that the VHH paratope is enlarged by an
extension of the CDR1 loop (Fig. 1B) (Nguyen et al.,
2000; Vu et al., 1997). Also the CDR3 loop in VHHs of
dromedary (less so in llama’s) contains longer loops
(average 16 amino acids) than in a VH from human or
mouse (average 14 or 12, respectively) (Muyldermans
et al., 1994; Vu et al., 1997; Wu et al., 1993). Evidently,
longer loop lengths (havingmore amino acids) increase the
paratope size (Fig. 1B).
Much of the paratope diversity in classical antibodies
originates from the VH–VL pairing. Such combinatorial
diversification is obviously absent in the paratope of a VHH
as there is no VL domain in HCAbs. This limitation in the
paratope repertoire is compensated by the antigen-
binding loops that adopt novel conformations, never
observed in human or mouse VHs. Indeed, the crystal
structures of VHHs reveal that the antigen-binding loops of
a VHH do not follow the canonical structural restrictions,
and apparentlymanymore loop architectures can be found
in VHH’s than in VHs (Decanniere et al., 2000; Nguyen
et al., 2000, 2001). The rationale to introduce this loop
diversification, especially in the CDR1, is embedded in the
germline sequences in a subtle but ingenious way. By a
substitution of two Phe codons (TTY) at positions that are
detrimental for the loop organization, into Tyr codons
(TAY), the CDR1 in a VHH acquires two additional hotspots
(TA dinucleotides) for somatic hypermutations (Conrath
et al., 2003; Nguyen et al., 2000). Indeed, the amino acids at
these positions in the CDR1 are much less conserved in
VHH than in VH.
Probably, the impact of the CDR1 and CDR2 on the
antigen recognition has to be limited since the crystal
structure survey on dromedary VHH’s in complex with
lysozyme indicated that the CDR3 is the main contributor
of antigen binding (De Genst et al., 2006b).Whereas the six
loops of a VH–VL pair contribute more or less equally to
antigen binding, in a VHH the CDR3 loop dominates by
providing at least 60–80% of the contacts with antigen.
Moreover, we noticed that the VHH accumulatesmany and
surprisingly convergent somatic hypermutations, prob-
ably during the affinity maturation process during
immunization (De Genst et al., 2004, 2005).
Apart from the increased paratope repertoire generated
by a greater diversity in the architecture of antigen-
binding loops, the single-domain format leaves a footprint
of its paratope on the antigen that is only half the size as
opposed to that of the two-domain format (VH–VL) of
classical antibodies. The VHH paratope, often helped by a
protruding long CDR3 loop (De Genst et al., 2006b;
Desmyter et al., 1996), is also convex shaped, in contrast
to the VH–VL paratope that is either forming a concave or
flat surface. Consequently, it came as no surprise to find
that dromedary VHH’s target preferably the antigen
surfaces with concave topology such as the clefts forming
the active site of enzymes (Lauwereys et al., 1998). This
HCAb bias for unique epitopes that differ from preferred
epitopes of classical antibodies was supported repeatedly
by the observation that VHHs often act as enzyme
inhibitors (or activators) (Lauwereys et al., 1998; Transue
et al., 1998; Desmyter et al., 2002; Saerens et al., 2004), a
finding that was contradicted for llama HCAbs (Ferrari
et al., 2007).
2. HCAb generation
It can be inferred, fromhomologywith human ormouse
IgH chromosome loci, that the dromedary genome
contains a cluster of VH and VHH germline genes, followed
by a pool of D genes, a pool of J genes and the C genes
including m, g, e, a. The presence of a Cd gene in the llama
or dromedary IgH locus is uncertain, as it has been for a
long time in artiodactyls (pigs) as well (Zhao et al., 2002).
However, it is clear that the dromedary genome contains
multiple Cg genes, some of which are dedicated to
constitute the conserved part of the H-chain of HCAbs
whereas other Cg genes are employed to produce the H-Please cite this article in press as: Muyldermans, S., et al., Camelid immunoglobulins and nanobody technology. Vet.
Immunol. Immunopathol. (2008), doi:10.1016/j.vetimm.2008.10.299
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Imin of classical Abs (Nguyen et al., 2003; Zou et al., 2005).
dromedary genome contains about 50 VH and 40 VHH
mline genes. The VHH germline genes have their Cys
oded in the CDR1 region, and the characteristic amino
substitutions within the VHH-framework-2 region
uyen et al., 1998). The exact number of D genes is
nown, however, it seems that the J clusters comprises
genes (the most upstream (50 located) gene might be a
udogene) (De Genst et al., 2006a). Since the same D and
nes can be rearranged to either one of the VH or one of
VHH germline genes, it is probably safe to conclude
t VH and VHH are part of the same locus (De Genst et al.,
6a; Nguyen et al., 2000). After VDJ rearrangement it
ms that the Cys is introduced somatically in the CDR3
ion for VHH but not so for VH domains. As it is difficult
imagine how this is accomplished during the DNA
ombination, it is most likely a consequence of a sub-
uent selection, i.e. rearranged VHH regions without a
codon in their CDR3will not survive the B cell selection
cess, or need to knock-out the Cys codon in their CDR1.
Much of our current knowledge on the human or mouse
ell ontogeny and maturation came from transgenic
use models. However, in the case of the ontogeny of B
s producing bona fide HCAbs, the data from transgenic
e yielded even conflicting results (Bru¨ggemann et al.,
6). For example, a transgenic mice expressing the
medary rearranged VHH–DJ joined to the HCAb dedi-
ed Cg2a gene produced an H-chain transcript in which
CH1 exon was deleted (and consequently the CH1
ain in the H-chain polypeptide as well). A single-point
tation from the conservedGT at the 50 splicing site of the
intron to AT was held responsible for this special VHH to
hinge splicing (Zou et al., 2005). In contrast, a transgenic
mouse carrying the humanCg genewith the samemutation
at the splicing site failed to remove the CH1 exon from the
transcript (Janssens et al., 2006). The current knowledge
predicts that in the pre-B cell stage, the rearranged H-chain
is expressed and retained in the endoplasmic reticulum (ER)
by BiP chaperones that bind at the V and CH1 domains. The
two BiP chaperones per H-chain need to be replaced by the
surrogate L-chain complex to expose the pre-B cell receptor
on the cell surface, to trigger the allelic exclusion, to initiate
the L-chain rearrangement and to stop the expression of the
VpreB and l5 surrogate L-chain components (Martensson
et al., 2007) (Fig. 2). The functional surrogate L-chain
complex consists of the VpreB- and the l5-associated
polypeptides, whereby the VpreB functions as a VL
substitute and the l5 as a CL substitute. According to our
unpublished data the rearranged VHH–DJ domain is
expressedwith the CmH-chain containing the CH1 domain.
It is difficult to envisage how this single BiP attached to this
Cm1 domain and retaining the H-chain in the ER will be
replaced by the surrogate L-chain complex to secrete the
VHH-pre-B cell receptor (Fig. 2A). Our current working
hypothesis foresees that no pre-B cell receptor can bemade
with the VHH–DJ in association with the Cm, and therefore
the signal to initiate the L-chain rearrangement cannot be
given.Normally, suchBcellswill go intoapoptosis, however,
in case of HCAb ontogeny, a Cm to Cg class switch might
be attempted for the B cell to survive. In any case, after
the VHH–DJ rearranged genes have been switched in the
dromedaryH-locus fromCm to one of the Cg geneswith the
1. (A) From left to right the composition of a classical antibody (left), a heavy-chain antibody (middle) and a single-domain antigen-binding entity
ved from a heavy-chain antibody, the VHH or nanobody (right). The domain structure within the H-chain and L-chains shown. (B) The sequence
nization of the VH and VHHwith framework and CDR’s is schematically represented at the top of this panel. The hallmark amino acids in framework-2
in the VHH are given, as well as the inter-CDR disulfide bond occurring in the dromedary VHH. Below is the folded structure of the VH (left) and VHH
ain (right with its four b-stranded sheet (back) and the five b-stranded sheet in front). The hallmark VHH residues in framework-2 are shown as
res.ease cite this article in press as: Muyldermans, S., et al., Camelid immunoglobulins and nanobody technology. Vet.
munol. Immunopathol. (2008), doi:10.1016/j.vetimm.2008.10.299
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VETIMM-7914; No of Pages 6GT toATmutation, there is apparentlyno further problem to
produce HCAbs (Fig. 2B). The VHH domain should not be
captured by the BiP, since the CH1 domain is absent in the
dedicated Cg genes for HCAbs due to this point mutation at
the 30 end consensus splicing signal of the CH1 exon region
(Elkabetz et al., 2005; Nguyen et al., 1999; Woolven et al.,
1999).
3. Applications with Nbs
Genetic engineering techniques allow for a fast cloning
and selection of antigen-specific VHH’s, referred to as Nbs.
The Nbs can in theory be selected from vast, synthetic or
naı¨ve VHH libraries (Tanha et al., 2001; Verheesen et al.,
2006; Yau et al., 2003), although these often recognize the
antigen with low affinity, and therefore we opt for a prior
immunization of a dromedary or llama as this gives us
affinity-matured Nbs. Immunizing a llama or dromedary
by repeated subcutaneous injections in presence of
adjuvant is performed as in any other mammal (e.g. goat
and rabbit). After a short immunization step (6–7 weeks)
we purify the lymphocytes from a lymph node biopsy or a
50–100-ml peripheral blood sample and after an RT-PCR
sample in a phage display vector (Nguyen et al., 2001;
Saerens et al., 2004). The VHHs are expressed at the tip of
the phage particles and after 2–3 rounds of panningwe can
identify the individual clones producing virions harboring
an antigen-specific VHH. This method of identifying Nbs
from ‘immune’ libraries is much more efficient than
corresponding methods to identify antigen binders from
immune scFv or Fab libraries. In case of classical antibodies
the VH–VL pairs of the B cell receptor (BCR) are matured as
a VH–VL heterodimer. During the cloning of the domains of
the paratope, the VH and VL are amplified separately by
PCR and joined at a later stage. This makes that for 105
different BCR’s one needs to amplify 105 different VH gene
regions and 105 different VL gene regions that later have to
be joined in 1010 clones to encompass the entire repertoire
from which to retrieve the original VH–VL pair that
matured as an entity. In contrast, for the HCAb-type BCR’s
of 105 different B cells, one needs to clone a repertoire of
105 VHHs only as each VHH gene is comprised in one single
gene fragment of 350 bp. The retrieval of antigen-specific
VHHs from such (relatively) small libraries is evidently
much simpler than from large libraries.
Once a clone with an antigen-specific VHH is identified,
Fig. 2. (A) The translation product of the VH-Cm gene in the pre-B cell is kept in the endoplasmic reticulum by the BiP protein. These are replaced by the
surrogate light chain (VpreB andl5) and the complex is expressed as a B cell receptor (top panel). In case of a VHH-Cm polypeptide, only thel5 could bind to
Cm1,whereas the VpreB is expected to fail to pairwith the VHHdomain due to the hallmark framework-2 amino acids (lower panel). (B) In themature B cell,
a VH-Cm is assembled with the rearranged L-chain and expressed on the surface of the cell as an IgM. After class switch the same VH is joined to a Cg to
produce the BCR or the soluble IgG1 (middle panel). In case of a VHH-Cg expression with a CH1 exon deleted, we expect that a dimer of this polypeptide is
immediately expressed on the B cell surface or secreted in the serum as IgG2 or IgG3 HCAbs (lower panel).it is normally straightforward to express mg quantities ofwe clone the VHH repertoire from the B lymphocytes in thePlease cite this article in press as: Muyldermans, S., et al., Camelid immunoglobulins and nanobody technology. Vet.
Immunol. Immunopathol. (2008), doi:10.1016/j.vetimm.2008.10.299
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Imsoluble, properly folded Nb in bacterial systems, and
sts produce even larger quantities (Frenken et al., 2000;
der Linden et al., 2000). In contrast, the expression of,
scFv is routinely 10 times lower than the expression
els for Nbs. In addition, the stability of Nbs is higher
pared to that of scFv independent of whether the shelf
, the thermal stability, the stability against unfolding
h chemical denaturants or the protease resistance are
sidered (Dumoulin et al., 2002; Harmsen et al., 2006).
successful gut-passage of Nbs in a functional formwas
orted by Ablynx (www.ablynx.com). While the speci-
ty and the affinity of the Nb competes easily with the
ter scFv or Fabs, the strict monomeric behavior and its
all gene of only 350 bp makes the Nb ideal to tailor into
er bivalent or bispecific constructs (Conrath et al.,
1).
In our laboratory and in that of others as well, the Nbs
e been used as a research tool and in a variety of
gnostic or therapeutic applications. To increase the
satility of the VHH, a stable VHH domain has been
ntified that is well expressed and acts as a loop acceptor
raft the loops of other, less stable or lesswell expressed,
Hs and thereby arriving at a chimeric domain with an
anced stability, better expression and with the antigen
cificity and affinity of the loop donor VHH (Saerens
l., 2005).
In another effort we have cloned the pig Fc isotypes
ind a Nb to arrive at a chimeric HCAb composed of a
H-pigFc (see article by Butler et al., this issue). This
meric protein is used to generate monoclonal anti-
ies against pig IgG isotypes. Following the same
tegy of generating genetic man-made constructs with
Nb gene fused to b-lactamase, or a truncated gene
sionof thehumanApoLI ormRFP (apolipoprotein L–I or
nomeric red fluorescent protein, respectively) we
ained interesting constructs for therapeutic-, or
earch purposes (Baral et al., 2006; Cortez-Retamozo
al., 2004; Rothbauer et al., 2006). The lactamase
ion construct comprised a Nb directed against car-
o-embryonic antigen (CEA), a human tumor marker.
e carrying a human tumor were injected with this
tein fusion to load the tumor with the conjugate. A
drug administered in the vein of the mice will be
verted to a highly toxic molecule by the lactamase.
sequently, a high concentration of the toxin is
duced, mainly in the vicinity of the tumor site. Follo-
g this antibody-dependent enzyme prodrug therapy
roach, we could eradicate – entirely and without
pse – the established solid tumors in mouse models
rtez-Retamozo et al., 2004).
With the construct of the truncated ApoLI attached to a
that recognizes the Trypanosome rhodesiensis, a
asite that causes sleeping sickness in East Africa, we
erated a strong trypanolytic compound that elimi-
ed the parasites from blood (Baral et al., 2006;
lemans et al., 2004). This Nb recognizes the conserved
bohydrate of the trypanosomal Variant surface glyco-
tein, the major coat protein that covers the entire
face of theparasite andwhich is exchangedbyone of its
iants during the antigenic variation, the main parasite
Finally, extending the Nb with the mRFP (referred to as
a chromobody) generated a useful tool to target and to
uncover the residence of antigen in living cells. Proof of
principle was given with Nbs directed against cytokeratine
and lamin (Rothbauer et al., 2006). Cell lines, transiently
transfected with the genetic constructs of the respective
Nb-mRFP revealed under the confocal microscope convin-
cing pictures where the antigens were stained with the
chromobodies. In addition, it has been proved recently that
Nbs tethered to a solid support are ideal to capture their
cognate antigen even when present at low doses in a
complex mixture (Rothbauer et al., 2008). Hence, we can
recommend the Nb as a highly antigen-specific tool for
immunoprecipitation, although in Western blots its
performance is rather poor.
In conclusion, antigen-specific Nbs are readily identi-
fied after a short immunization of a llama, a camel or a
dromedary with antigen, a cloning step of the VHH reper-
toire from the immunized animal and phage display. The
good expression in microbial systems and the beneficial
biochemical properties (good solubility, good stability in
harshconditions,highaffinityandspecificity for theantigen,
small size and strict monomeric behavior) make that Nbs
are an ideal tool for research purposes or diagnostic or
therapeutic applications.
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